What is TOMI Environmental's gross profit margin?

What were the key takeaways from TOMI Environmental's earnings call?

What is the market's earnings forecast for TOMI Environmental next quarter?

What were the key takeaways from TOMI Environmental’s earnings call?

What guidance did TOMI Environmental's management provide for the next earnings period?

Did TOMI Environmental beat or miss consensus estimates last quarter?

What factors drove the changes in TOMI Environmental's revenue and profit?

What is TOMI Environmental's latest dividend and current dividend yield?

- **Revenue Recovery**: Q3 2025 revenue up 95% sequentially to $2 million, driven by BIT Solution sales (21% YTD growth) and equipment purchases.
- **FDA Breakthrough**: Hydrogen peroxide approval for food safety opens $3+ billion RTE market; direct food surface disinfection now possible.
- **Strategic Capital**: $20M equity purchase agreement provides funding flexibility for 2026 growth initiatives.
- **Key Wins**: New customers include Bausch & Lomb, Nestle, and major pharma companies; $3M custom automation pipeline.
- **Gross Margin Resilience**: 61% gross margin maintained despite 24% YoY revenue decline.

**【CEO Summary Section】**
- Q3 2025 revenue reached $2 million, a 95% sequential increase driven by recurring BIT Solution sales (up 21% YTD) and capital equipment purchases from service providers.
- Sales backlog grew to $1.3 million by end of October, with $3 million in pending SteraMist Integration Contracts expected to close by year-end.
- FDA approval of hydrogen peroxide for food safety opens new markets, including RTE (ready-to-eat) food processing and transportation.
- Strategic partnership with Hudson Global Ventures provides $20 million equity purchase flexibility for scaling initiatives.

**【CFO Financial Commentary】**
- Q3 2025 revenue ($2 million) declined 24% YoY due to delayed iHP services from a key customer, but year-to-date service demand rose 35% in life sciences/food safety.
- Gross margin remained strong at 61%, while operating loss was $320,000 vs. $149 million profit in Q3 2024.
- Cash reserves of $190,000 and working capital of $2.5 million support near-term operations.

**【COO Business Highlights】**
- New customers include Bausch & Lomb (eye health) and Nestle (food safety), with SteraMist deployments across 20+ countries.
- FDA approval enables direct food surface disinfection, targeting RTE food processing, packaging, and transportation.
- Pharmaceutical industry adoption growing with SteraMist Integrated Systems (SIS) for bioprocessing automation.
- $3 million pipeline in custom automation solutions for 2025 close.

**【Q&A Highlights】**
- **Food Safety Expansion**: FDA approval validation efforts underway with major food processors; initial focus on RTE, prepackaged meals, and transportation.
- **Military & Defense**: Engaged with U.S. military on formaldehyde replacement studies; expects 2026 deal.
- **Data Center Market**: Exploring partnerships for large-scale facility disinfection; sales team expansion planned.
- **Medical Sterilization**: Testing SteraMist as ethylene oxide alternative for medical device sterilization.
- **Operating Expenses**: Expect revenue growth to outpace expense increases, maintaining ~60% gross margin.

TOMZ

TOMZ fundamentals

You can ask Aime